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Abstract
Methamphetamine (MA) addiction is a growing epidemic worldwide. Chronic MA use has
been shown to lead to neurotoxicity in rodents and humans. Magnetic resonance imaging
(MRI) studies in MA users have shown enlarged striatal volumes and positron emission
tomography (PET) studies have shown decreased brain glucose metabolism (BGluM) in
the striatum of detoxified MA users. The present study examines structural changes of the
brain, observes microglial activation, and assesses changes in brain function, in response
to chronic MA treatment. Rats were randomly split into three distinct treatment groups and
treated daily for four months, via i.p. injection, with saline (controls), or low dose (LD) MA
(4 mg/kg), or high dose (HD) MA (8 mg/kg). Sixteen weeks into the treatment period, rats
were injected with a glucose analog, [18F] fluorodeoxyglucose (FDG), and their brains were
scanned with micro-PET to assess regional BGluM. At the end of MA treatment, magnetic
resonance imaging at 21T was performed on perfused rats to determine regional brain vol-
ume and in vitro [3H]PK 11195 autoradiography was performed on fresh-frozen brain tissue
to measure microglia activation. When compared with controls, chronic HD MA-treated
rats had enlarged striatal volumes and increases in [3H]PK 11195 binding in striatum, the
nucleus accumbens, frontal cortical areas, the rhinal cortices, and the cerebellar nuclei.
FDGmicroPET imaging showed that LD MA-treated rats had higher BGluM in insular and
somatosensory cortices, face sensory nucleus of the thalamus, and brainstem reticular for-
mation, while HD MA-treated rats had higher BGluM in primary and higher order somato-
sensory and the retrosplenial cortices, compared with controls. HD and LD MA-treated rats
had lower BGluM in the tail of the striatum, rhinal cortex, and subiculum and HDMA also
had lower BGluM in hippocampus than controls. These results corroborate clinical findings
and help further examine the mechanisms behind MA-induced neurotoxicity.
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Introduction
Methamphetamine (MA) is a widely abused drug with devastating health effects [1]. MA
increases extracellular concentrations of dopamine (DA), norepinephrine (NE) and serotonin
(5HT) by acting on the transporter of each neurotransmitter [2–4] and by reversing neuro-
transmitter transport direction [5]. Chronic abuse of MA has been associated with damage to
DA and 5HT terminals [5–7].
Additionally MA is rapidly taken by various organs in the body, including the lungs, brain,
liver, pancreas, stomach, and kidneys, where it clears slowly [8], which could explain the associ-
ation between MA and pulmonary hypertension [9] and kidney damage [10] among others.
However, most MA studies have focused on the central nervous system. Studies in humans and
non-human primates using magnetic resonance imaging (MRI) have shown structural abnor-
malities in the brain of MA users, including lower gray matter volumes [11], increased white
matter volumes [11], enlarged striatal volumes [12–17] and larger volumes of the parietal cor-
tex [14]. This increased brain volume in MA users has been hypothesized to reflect inflamma-
tory changes in these brain regions, including microglial activation, and has been positively
correlated with deterioration of performance in reversal learning [17]. Still, volumetric
increases in the striatum of MA users have also been positively correlated with novelty seeking
[15] and with improved cognitive performance [13, 16], which suggests that increased striatal
volume after MA use may also reflect compensatory changes in response to MA-induced
neurotoxicity.
Using positron emission tomography (PET) and the glucose analog fluorodeoxyglucose
(FDG), regional brain glucose metabolism (BGluM) has been assessed in MA users. In detoxi-
fied MA users, metabolic activity was increased in the parietal cortex and decreased in the thal-
amus and striatum [18, 19], although some recovery of function was seen in the thalamus after
protracted abstinence [19]. Other studies have reported increased metabolism in the parietal
cortex [20], increased metabolism in the cingulate, amygdala, ventral striatum, and cerebellum,
but decreased metabolism in the insular and orbitofrontal area in abstinent MA users [21]. In
addition PET studies have reported a downregulation of DA transporters (DAT) [22] and of
DA D2 receptors in the striatum of MA abusers [23] with evidence of some recovery in DAT
levels after protracted detoxification [24, 25]. Finally PET studies using [11C]PK 11195, which
serves as a marker of microglia activation have also provided evidence of neuroinflammatory
changes in the brain of MA users [26].
Together, these studies show that chronic MA use can lead to structural and functional brain
deficits, although the possibility of pre-existing vulnerabilities in the brain of humanMA users
cannot be excluded. To further characterize the effects of long termMA use, the present study
examined in rodents, the structural changes using magnetic resonance imaging (MRI), func-
tional changes using PET to measure regional BGluM, and microglial activation with in vitro
[3H]PK 11195 autoradiography. We hypothesized that chronic MA treatment would result in
structural and functional deficits throughout the brain and that these effects would be potenti-
ated in regions linked to the dopaminergic system, including the striatum and the nucleus
accumbens. Furthermore, [3H]PK 11195 autoradiography would allow us to assess if MA-
induced structural and functional changes in the brain were associated with neuroinflammation.
Methods and Materials
Animals
Sprague Dawley (SD) rats were purchased from Taconic farms (NY). All rats were male and 4
weeks old at the start of the study. Animals were individually housed in clear plexi-glass cages,
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with wire covers under standard laboratory conditions (22±2°C, 50±10% relative humidity),
and a reverse12h/12h light/dark cycle, with lights on at 8 P.M. and off at 8 A.M. All experimen-
tal sessions were conducted during the rats’ dark cycle. Food and water were available ad-libi-
tum, except the night before μPET scans when rats were food deprived, similar to previous
FDG micro positron emission tomography (μPET) studies [27]. All experiments were con-
ducted in conformity with the National Academy of Sciences Guide for the Care and Use of
Laboratory Animals (NAS, 1996) and the University of Buffalo IACUC protocol RIA13095Y.
Drugs
MA hydrochloride was purchased from Sigma-Aldrich (St. Louis, MO). MA was prepared by
dissolving MA hydrochloride in saline solution to produce concentrations of 4 mg/kg and 8
mg/kg. After a one week acclimation period to the animal facility, rats began MA treatment.
Rats were randomly assigned to receive vehicle (saline), or low dose (LD) 4mg/kg MA, or high
dose (HD) 8 mg/kg MA, via daily intraperitoneal injections for four months (1 ml/kg body
weight).
Procedures
Structural magnetic resonance imaging. At the end of MA treatment, rats (n = 6 vehicle,
n = 5 LD, n = 8 HD) were transcardially perfused with 4% paraformaldehyde and the heads
were scanned on a 21.1T Biospin Advance scanner. T2-weighted MR images were generated
with the following parameters: TE = 7.5 ms, TR = 150 ms, FOV = 3.40 cm x 3.12 cm x 3.00 cm,
voxel size = 0.08 mm x 0.08 mm x 0.08 mm, scan time 12 hrs. Brains scans were aligned to a
common space with rigid transformations using RView, (http://colin-studholme.net [28]) and
were manually segmented with the use of the modeling and visualization package Amira 4.1
(Visage Imaging Inc, Andover, MA). Segmentations were guided by the rat brain stereotaxic
atlas by Paxinos and Watson [29]. Volumes are reported in mm3.
[3H]PK 11195 autoradiography. Following the last day of treatment, rats were anesthe-
tized using isoflurane and decapitated. The brains were rapidly removed, flash-frozen in
2-methylbutane, and stored at -80°C until use (n = 5 / group). Cryostat sections (14 μm thick)
were cut, mounted on slides, and stored tightly sealed at -80°C in the presence of desiccant,
until the day of the binding experiment.
[3H]PK 11195 binding was carried out according to previously established protocol [30, 31].
Sections were pre-incubated for 15 min in 50 mM Tris-HCl buffer (pH 7.4) at room tempera-
ture. Sections were then incubated in pre-incubation buffer with the addition of 0.8 nM [3H]
PK 11195 (85.7 Ci/mmol, PerkinElmer Inc.) for 30 min at room temperature. Non-specific
binding was determined on consecutive sections in the presence of excess 20 μM unlabelled PK
11195. At the end of the incubation, sections were washed twice for 6 minutes in ice-cold 50
mM Tris HCL buffer (pH 7.4) and then dipped in ice-cold distilled water.
After binding, all sections were dried under a stream of cool air and exposed onto Kodax
BioMax MR Film, alongside calibrated tritium standards (American Radiolabeled Chemicals,
St. Louis, MO). After 8 weeks of exposure, the films were developed in Kodax D-19 developer,
dried and scanned as a TIFF image. All regions of interest were quantified using the calibrated
standard curves and the Image J software (NIH). Regions of interest (ROI) selected include
major areas of the cerebral cortex: prelimbic/infralimbic, cingulate, retrosplenial, insular, rhi-
nal, motor (M1 &M2), piriform, somatosensory, auditory, and visual. Sub-cortical areas
selected for analysis include: nucleus accumbens, amygdala, striatum, cerebellum (cortex and
nuclei), colliculi, hippocampus, hypothalamus, periaqueductal gray, septum, substantia nigra,
and thalamus.
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Brain Glucose Metabolism using [18F] FDG and μPET. BGluM was assessed 16 weeks
into the treatment period (n = 7 vehicle; n = 9 LD; n = 6 HD), using [18F] FDG and μPET.
Briefly (see Fig 1 for timeline), 5 minutes following MA or saline (for vehicle treatment group)
injections, rats were injected i.p. with [18F] FDG (~750 μCi ± 250 μCi). After a 30 minute
awake uptake period in the home cage, rats were anesthetized with isoflurane and scanned for
30 minutes in a μPET R4 scanner (transaxial resolution = 2.0 mm full width at half maximum,
field of view = 11.5 mm; Concorde CTI Siemens, Knoxville, TN).
Image analysis was performed as previously described [32]. Briefly, images were recon-
structed using a MAP algorithm with 15 iterations, 0.01 smoothing value and a 256 x 256
resolution. After reconstruction, voxel size was x = 2.0, y = 2.0, z = 2.0 mm. All images were
spatially normalized and co-registered to the Schweinhardt MRI template (Schweinhardt et al.
2003) using the PMOD software (PMOD Technologies, Zurich, Switzerland). Using the statis-
tical parametric mapping software (SPM 8), images were then smoothed (4 mm Gaussian) and
a one-way Analysis of Variance (ANOVA) was run to assess significant differences in meta-
bolic activity between treatment groups. Comparisons between groups were made at Ke = 50
voxels and a = 0.01. These numbers correspond to the minimum number of voxels compared
between treatment groups that show significant differences in BGluM with an alpha level set
at 0.01.
Brain regions that showed significant differences were overlaid onto the Schweinhardt MRI
atlas [33] in Paxinos space, and assessed using the stereotaxic atlas by Paxinos and Watson
[29]. Increased BGluM was defined as greater metabolism in MA treated rats (either LD or
HD) when compared to vehicle treated rats. Decreased BGluM was defined as greater metabo-
lism in vehicle treated rats when compared with MA (either LD or HD) treated rats.
Statistics
MRI measures were analyzed with one-way Analysis of Variance (ANOVA), with treatment as
between-subjects factor. Analysis of Co-Variance (ANCOVA) with total brain volume as co-
factor was also performed. When appropriate, Bonferroni post-hoc test was applied to assess
the significant pairwise differences. Auroradiographic [3H]PK 11195 measures were analyzed
with one-way ANOVA, followed by Holm-Sidak post hoc comparisons when appropriate.
Level of significance was set at p<0.05.
Results
MRI
The volumes of the regions of interest are presented in Fig 2 and Table 1. The volume of the
striatum was significantly higher by 15% in rats treated with HD-MA, compared with the vehi-
cle group (one-way ANOVA, F (2, 16) = 4.35, p = 0.031; Bonferroni post-hoc, p = 0.036). The
volume increase was uniform throughout the striatum. No statistically significant treatment x
slice interaction was observed for the volume of the striatum along the anteroposterior axis
(Fig 3). No statistically significant differences in the volume of the total brain, the cerebral
cortex, the hippocampus, the globus pallidus, the cerebellum, and the external capsule were
observed between groups. Analysis of co-variance, taking into consideration total brain vol-
ume, did not yield further or different results.
[3H]PK 11195 Autoradiography
Representative sections showing the levels and distribution of [3H]PK 11195 binding in MA-
treated and control rats are shown in Fig 4.
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Measures of [3H]PK 11195 specific binding were analyzed with one-way ANOVA. In corti-
cal ROIs, a significant effect of treatment was found in the insular (F (2, 13) = 5.258, p< 0.05),
cingulate (F (2, 13) = 6.490, p< 0.05), prelimbic (F (2, 13) = 7.817, p< 0.05), and rhinal
(F (2, 13) = 4.993, p< 0.05) cortex. Pairwise comparisons using the Holm-Sidak method
showed that in these regions HDMA treatment resulted in significantly higher specific [3H]PK
11195 binding over both vehicle and LDMA treatments (p<0.05; Fig 5a).
In subcortical ROIs, a significant effect of treatment was observed in the striatum (F (2, 13) =
5.172, p< 0.05), the nucleus accumbens (F (2, 13) = 4.861, p< 0.05), and the cerebellar nuclei
(F (2, 13) = 6.186, p< 0.05). Pairwise comparisons showed that in the striatum (p = 0.008; Fig 5b)
Fig 1. Outline of [18F] FDG μPET experiment. Five minutes following MA or vehicle injection, rats were injected with
FDG. After a 30 minute uptake in the home cage, rats were anesthetized and scanned for 30 minutes. T: time (min);
MA: methamphetamine; FDG: [18F]deoxyglucose; PET: positron emission tomography.
doi:10.1371/journal.pone.0155457.g001
Fig 2. Rat brain MRI slices and three-dimensional reconstruction. A-B Coronal (A) and horizontal (B)
brain MRI slices from a rat brain. C-D Outlined regions of interest from the same slices. E Three-dimensional
reconstruction of the segmented regions of interest; ventral view. Ctx: cerebral cortex, CPu: caudate-
putamen (striatum), GPe: globus pallidus, CC/EC: corpus callosum/external capsule, Cer: cerebellum.
doi:10.1371/journal.pone.0155457.g002
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and the nucleus accumbens (p = 0.01; Fig 5b), HDMA significantly increased [3H]PK 11195 spe-
cific binding compared with vehicle. In the cerebellar nuclei, LDMA treatment significantly
increased [3H]PK 11195, compared with vehicle (p = 0.008; Fig 5b).
Brain Glucose Metabolism (BGluM)
LDMA treatment resulted in increased BGluM (LD> Vehicle; Fig 6, Table 2) in insular cortex
(panels 1–2), somatosensory cortex (panels 4–5), ventral posteromedial thalamic nucleus
(panel 6), and isthmic reticular nucleus (panels 8–9). Decreased BGluM (LD< Vehicle;
Table 2, Fig 6) was observed in cingulate cortex (panels 2–3), ventral pallidum (panel 4), tail of
the striatum (panel 5), rhinal cortex (panels 6–9), and subiculum (panel 9).
HDMA treatment resulted in increased BGluM (HD> Vehicle; Fig 7, Table 3) in primary
somatosensory cortex (panels 1–3), parietal association area (panel 4), and retrosplenial cortex
(panel 9). Decreased BGluM (HD< Vehicle; Table 3, Fig 7) was observed in globus pallidus
and tail of the striatum (panel 3), hippocampus (CA2 region, panels 5–6), and rhinal cortex
(panels 6–7).
Between MA doses, increased BGluMwith HDMA (HDMA> LDMA; Fig 8, Table 4) was
observed in parietal association area (panels 3–4), retrosplenial cortex (panels 3–5), and somato-
sensory cortex (panel 1). Increased BGluMwith LDMA (LDMA>HDMA; Fig 8, Table 4) was
observed in the temporal association area and paragigantocellular nucleus (panel 6).
Table 1. Effects of chronic methamphetamine administration on regional rat brain volume.
Vehicle 4 mg/kg MA 8 mg/kg MA
Striatum 87.2 ± 3.6 99.6 ± 2.7 100.6 ± 3.9 *
Globus pallidus 11.9 ± 1.1 12.7 ± 1.3 11.8 ± 0.6
Cerebral cortex 748.7 ± 9.5 803 ± 11.4 763.4 ± 17.2
Hippocampus 117.3 ± 2.9 126.2 ± 3.6 116.5 ± 4.1
Cerebellum 324.3 ± 7.9 362.1 ± 17.9 348 ± 9.5
External capsule 107.8 ± 4.9 110 ± 3.7 107.9 ± 3.3
Total brain 2592.4 ± 39 2708.7 ± 95.2 2633.9 ± 43.1
The numbers represent mean ± SEM, expressed in mm3.
* denotes significant difference from vehicle, p<0.05.
doi:10.1371/journal.pone.0155457.t001
Fig 3. Volume of the striatum along the antroposterior axis. A Average volume of each MRI slice along
the anteroposterior axis, from the three treatment groups. B Average volume of consecutive segments of the
striatum, 720um each (9 slices), along the anteroposterior axis. The points and bars represent mean + S.E.M.
Zero on the X axis corresponds to the posterior part of the anterior commissure. Distance is in mm.
doi:10.1371/journal.pone.0155457.g003
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Discussion
Here we show that a daily dose of HDMA (8 mg/kg) for four months can cause increases in
the volume of the striatum and increases in microglial activation in the striatum. Chronic MA
treatment also resulted in significant changes in BGluM. Increases in BGluM were found in
several areas including primary and higher order somatosensory regions, while decreases in
BGluM were found in the tail of the striatum, hippocampus, and rhinal cortices.
HDMA-treated rats present enlarged striatum
In the current study, enlarged striatal volume was observed after chronic MA treatment. A sim-
ilar finding was also observed in clinical and non-human primate studies that report increases
in striatal volume in abstinent as well as active MA users [12–17]. Although structural brain
deficits may pre-date MA use in humans, the coincidence among rat, monkey, and human
findings allows us to suggest that enlarged striatal volume is a major and long-lasting effect of
chronic MA use.
In addition, a unique aspect of this study is that the onset of MA treatment began at adoles-
cence. Human studies on the effects of chronic MA use exclusively in adolescence [15] or
chronic MA use starting at 12–34 years and extending into adulthood [16] report an increase
in the volume of the striatum, which is in agreement with our current anatomical findings and
confers clinical relevance to our rodent model of chronic MA exposure.
HDMA-treated rats present microglial activation in the striatum
It is well established that the peripheral benzodiazepine binding site, as determined with in
vitro and in vivo PK 11195 binding, is localized in activated microglia [34–37]. Activated
microglia may be cytotoxic, through the release of free oxygen species, nitrogen oxides such as
NO, and pro-inflammatory cytokines such as IFN-γ [38, 39]. In addition, microglial activation
takes place after neurotoxic amphetamine treatment [40] and before dopamine terminal
pathology [41], and could thus account for the impairment of dopamine neuron integrity and
Fig 4. Chronic MA treatment increases [3H]PK 11195 binding in the brain.Representative in vitro
autoradiographic images of [3H]PK 11195 binding in coronal brain sections of rats chronically treated with
vehicle or with LD MA (4mg/kg) or with HDMA (8mg/kg). Significant effects of methamphetamine treatment
on [3H]PK 11195 specific binding were observed in the highlighted areas, i.e. PrL: prelimbic cortex, Ins:
insular cortex, Cing: cingulate cortex, CPu: caudate-putamen (striatum), nAc: nucleus accumbens, Rhi: rhinal
cortex, dcn: deep cerebellar nuclei.
doi:10.1371/journal.pone.0155457.g004
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Fig 5. [3H]PK11195 specific binding in cerebral cortical (A) and subcortical (B) brain regions of rats
chronically treated with vehicle or LDMA (4mg/kg) or HDMA (8 mg/kg). The bars represent mean + S.E.
M. of [3H]PK11195 specific binding on fresh-frozen brain sections. * compared with vehicle and 4 mg/kg MA,
+ compared with vehicle.
doi:10.1371/journal.pone.0155457.g005
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dopamine system function observed after chronic methamphetamine use (Thanos et al in
preparation, [42]).
On the other hand, activated microglia also have a protective role for the brain, since they
promote neurogenesis [43], they remove toxic glutamate levels [44], and they contribute
to tissue remodeling be removing cellular debris [38]. Most importantly, they express and
release a number of neurotrophic factors, including nerve growth factor (NGF), brain derived
Fig 6. Effects of chronic LDMA (4mg/kg) treatment on regional brain glucosemetabolism. Changes in
regional brain glucose metabolism are superimposed on the Schweinhardt MRI template, in Paxinos space.
Red: brain regions with increased glucose metabolism after 4 mg/kg MA treatment compared with vehicle
treatment; Blue: brain regions with decreased glucose metabolism after 4mg/kg MA treatment compared with
vehicle treatment. IC: insular cortex, Cg: cingulate cortex; S1: primary somatosensory cortex; VP: ventral
pallidum; CPu: caudate-putamen (striatum); Rhi: rhinal cortices; VPM: ventral posteromedial thalamic
nucleus; isRt: isthmic reticular formation; Sub: subiculum.
doi:10.1371/journal.pone.0155457.g006
Table 2. Brain regions showing significant differences in BGluM in rats treated with LD MA (4mg/kg) compared with vehicle.
p < 0.01 Ke > 50 Brain Region Cluster Level Stereotaxic Location
of Peak (mm)
(Ke) t value z score p x y z
Increased BGluM primary somatosensory cortex (S1) 328 5.38 4.06 0 6.3 3.2 -2.3
LD MA > veh insular cortex (Ins) 177 3.76 3.16 0.001 -3.9 5 4.3
ventral posteromedial thalamic nucleus (VPM) 145 3.43 2.95 0.002 -3.7 5.6 -3.3
Decreased BGluM rhinal cortex (Rhi) 1039 6.19 4.42 0 6.7 6.8 -5.5
LD MA < veh Striatum / subiculum (CPu/Sub) 773 4.63 3.68 0 -5.9 6.4 -4.3
striatum-tail 4.15 3.4 0 -4.9 6.6 -2.7
subiculum 4.07 3.36 0 -5.3 5.2 -7.1
Cingulate cortex (Cg1) 108 3.84 3.21 0.001 1.0 1.0 1.3
LD: low dose; MA: methamphetamine; Veh: vehicle (saline); Increased BGluM: Significant clusters (Ke = 50) where metabolic activity was greater in LD
MA treated rats compared with vehicle (α = .01); Decreased BGluM: Significant clusters (Ke = 50) where metabolic activity was lower in LD MA treated
rats compared with vehicle (α = .01).
doi:10.1371/journal.pone.0155457.t002
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neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), fibroblast
growth factor (FGF) [38, 39], and they induce dopamine terminal sprouting through the
release of BDNF and GDNF in the striatum [45, 46].
Given that BNDF enrichment of the brain can produce volumetric increases [47], we could
hypothesize the existence of a pathway linking methamphetamine exposure to microglia acti-
vation, neurotrophin secretion, and increased volume in the striatum. Such a mechanism could
Fig 7. Effects of chronic HDMA (8mg/kg) treatment on regional brain glucosemetabolism. Changes in
regional brain glucose metabolism are superimposed on the Schweinhardt MRI template, in Paxinos space.
Red: brain regions with increased glucose metabolism after 8mg/kg MA treatment compared with vehicle
treatment; Blue: brain regions with decreased glucose metabolism after MA 8mg/kg treatment compared with
vehicle treatment. M1: primary motor cortex; S1: primary somatosensory cortex; CPu: caudate-putamen
(striatum); GP: globus pallidus; PtA: parietal association area; CA1: cornu ammonis 2 (hippocampus); Rhi:
rhinal cortices; Sub: subiculum; RCS: retrosplenial cortex.
doi:10.1371/journal.pone.0155457.g007
Table 3. Brain regions showing significant differences in BGluM in rats treated with HDMA (8mg/kg) compared with vehicle.
p < 0.01 Ke > 50 Brain Region Cluster Level Stereotaxic Location of
Peak (mm)
(Ke) t value z score p x y z
Increased BGluM primary somatosensory cortex (S1) 251 4.14 3.39 0 6.1 3 -2.3
HD MA > Veh retrosplenial cortex (RSC) 73 3.47 2.98 0.001 1.1 1.8 -8.5
parietal association area (MPtA) 91 2.99 2.61 0.004 1.9 8 -3.3
Decreased BGluM rhinal cortex (Rhi) 694 5.26 4 0 6.7 6.6 -5.9
HD MA < Veh Subiculum / Hippocampus(Sub/Hipp) 428 3.97 3.29 0 -5.3 5.2 -7.3
hippocampus 3.39 2.92 0.002 -5.5 5.6 -5.1
globus pallidus / striatum tail (GP/CPu) 92 3.72 3.14 0.001 -4.7 6.8 -2.5
HD: high dose (8mg/kg); MA methamphetamine; Veh: vehicle (saline); Increased BGluM: Significant clusters (Ke = 50) where metabolic activity was
greater in HD MA treated rats compared with vehicle (α = .01); Decreased BGluM: Significant clusters (Ke = 50) where metabolic activity was lower in HD
MA treated rats compared with vehicle (α = .01).
doi:10.1371/journal.pone.0155457.t003
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explain the positive association between striatal volume and measures of cognitive function
observed in human methamphetamine users [13, 16]. However, the present study indicates
only an association between microglial activation and changes in brain volume. Further
research is warranted to prove that a causal link between increased microglial activation and
changes in brain volume indeed exists after chronic MA treatment.
Fig 8. Differential effects of 4 and 8 mg/kg MA treatments on regional brain glucosemetabolism.
Regional brain glucose metabolism differences between 4 and 8 mg/kg MA treatments, superimposed on the
Schweinhardt MRI template, in Paxinos space. Green: brain regions with increased glucose metabolism after
4mg/kg MA treatment compared with 8 mg/kg MA treatment. Blue: brain regions with decreased glucose
metabolism after 4mg/kg MA treatment compared with 8 mg/kg MA treatment. S1: primary somatosensory
cortex; M1: primary motor cortex; RSC: retrosplenial cortex; PtA: parietal association area; Vis: visual cortex;
RSC: retrosplenial cortex; GN: gigantocellular nucleus.
doi:10.1371/journal.pone.0155457.g008
Table 4. Brain regions showing significant differences in BGluM in rats treated with LD MA (4mg/kg) compared with HDMA (8 mg/kg).
p < 0.01 Ke > 50 Brain Region Cluster Level Stereotaxic
Location of Peak
(mm)
(Ke) t value z score p x y z
LD MA> HD MA temporal association area (TeA) 65 3.71 3.13 0.001 -7.3 4.2 -7.1
Paragigantocellular Nucleus (Gn) 164 3.55 3.03 0.001 1.1 7.6 -11.1
LD MA< HD MA parietal association / primary somatosensory / retrosplenial cortex 822 4.28 3.48 0 1.7 0.6 -3.3
primary somatosensory cortex (S1) 3.1 2.72 0.003 2.3 0.8 -0.7
retrosplenial cortex (RSC) 2.87 2.55 0.005 -0.5 0.6 -4.1
LD: low dose (4mg/kg); HD: high dose (8 mg/kg); MA: methamphetamine; LD MA > HD mg/kg MA: Significant clusters (Ke = 50) where metabolic activity
was greater in LD MA treated rats compared to HD MA treated rats (α = .01); LD MA < HD mg/kg MA: Significant clusters (Ke = 50) where metabolic
activity was lower in LD MA treated rats compared with HD MA treated rats (α = .01).
doi:10.1371/journal.pone.0155457.t004
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MA treatment causes significant microglial activation in DA-poor brain
regions
Although much of the focus on MA effects on the brain has been in the striatum, here we
extend our findings from the striatum and show microglial activation in other areas of the
brain. LDMA treatment resulted in increased [3H]PK 11195 specific binding in the cerebellar
nuclei compared with vehicle. HDMA treatment increased [3H]PK 11195 binding in the insu-
lar, cingulate, prelimbic, and rhinal cortices, in addition to increases in the striatum and the
nucleus accumbens. However, these cortical and cerebellar regions with increased [3H]PK
11195 binding did not show a significant change in their volume. This could suggest that
increased [3H]PK 11195 binding does not always correlate to an increase in volume in all brain
regions. It is possible that in these areas, with weak DA innervation, microglial activation may
follow a different timeline in correlating with brain morphology and/or a different line of func-
tion. In addition to its effects on dopaminergic cells, MA also affects neuronal function in cells
outside of the dopaminergic system [6, 48]. Indeed, a loss of serotonin and its uptake sites, loss
of norepinephrine, and changes in GABA and glutamate transmission have all been reported
[6]. Hence, subsequent microglial responses in these areas of the brain, that are known to be
affected by MA [7], were expected.
These preclinical findings have been extended to abstinent human MA users, showing
increased [11C]PK 11195 binding in many distinct brain regions in addition to the striatum,
including midbrain, thalamus, insular cortex, and orbitofrontal cortex [26]. In addition to
increased PK 11195 binding, other markers for inflammation, including widespread increases
in proinflammatory cytokines and chemokines have been observed in both animals and
humans [49, 50]. These results show that MA-induced effects can extend beyond dopaminergic
cells in the striatum, to cells outside the dopaminergic pathways. Finally, MA abuse is associ-
ated with significant reduction in cerebral blood flow which could render neuronal tissue
susceptible to damage from hypoxia which would also contribute to gliosis [51, 52]. These find-
ings all suggest that MAmay induce global microglial activation and subsequent widespread
changes within the brain [21, 26]. However, the exact cause of MA-induced increases in PK
11195 binding has yet to be identified and the extent to which these findings translate to a
behavioral phenotype remain unclear.
Increased BGluM after chronic MA treatment
LDMA treatment resulted in increased BGluM in the ventral posteromedial thalamic nucleus,
in face somatosensory cortex (whisker and upper lip), in the reticular formation, and in the
insular cortex. The ventral posteromedial thalamic nucleus projects to the somatosensory cor-
tex [53], and in particular to the whisker somatosensory cortex, in which increased BGluM was
also observed in LDMA-treated rats. These effects predict changes in face sensory processing
after extended MA exposure. Indeed, exposure to MA has been previously shown to induce
damage to whisker somatosensory cortical neurons, which was associated with increased ste-
reotypical whisker movements [54] and was prevented by the removal of whiskers [55, 56].
In addition, increased BGluM was also observed in the insular cortex and reticular forma-
tion. The insular cortex receives multi-modal sensory input from thalamic nuclei and forms
reciprocal connections with the limbic system [57, 58]. It has been proposed that the insular
cortex is involved in a variety of functions, including salience detection [59, 60]. Similarly,
the reticular formation is involved in sleep cycles, more specifically in promoting wakefulness
and inhibiting REM sleep [61, 62]. Increased BGluM in the insular cortex and reticular for-
mation during LD MA exposure are especially significant in light of past findings where MA
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has been shown to be effective in treating narcolepsy and inducing increased alertness in
humans [63, 64].
HDMA treatment resulted in increased BGluM in the whisker somatosensory cortex, the
parietal association area, and the retrosplenial cortex. Similar to LDMA treatment, increased
BGluM was specific to the barrel field region of the somatosensory cortex, indicating effects of
HDMA on face sensory processing. The higher BGluM in the HDMA the parietal area is in
agreement with the increased BGluM in the parietal cortex of MA users previously reported in
clinical studies [18, 20]. These patients showed impairment in the Grooved Pegboard task, in
which fine motor coordination is assessed, indicating a functional link with hyperactivity in the
parietal cortex [22]. More recently, fMRI studies in MA users have shown activation of parietal
regions during a delayed discounting task, where MA users were more likely to select a small
immediate reward [65].
In rodents, in addition to thalamocortical projections, sensory areas within the neocortex
are also known to project to the parietal association areas [66]. Im mammals, these regions are
involved in exploratory behavior and spatial recognition by use of the digits, hands, and limbs,
and in rodents the whiskers and snout [66]. Furthermore, the parietal association areas and the
retrosplenial cortex are two of the regions thought to be involved in the rodent default mode
network (DMN) [67]. The DMN is a set of interconnected brain regions, found to be less active
when an individual is focused and engaged in a task [68, 69]. Lu and colleagues [67] proposed
that the DMN in rats serves to integrate sensory information to guide behavior in anticipation
to changing environmental stimuli. Overall, the increased BGluM in the parietal association
area and the retrosplenial cortex are indicative of HDMA effects on higher order sensorimotor
processing and cognitive control.
Decreased BGluM after Chronic MA Treatment
Regions that showed decreased BGluM during exposure to LDMA include interconnected
areas of the limbic system, including cingulate cortex, rhinal cortices, and subiculum. The cin-
gulate cortex sends projections to the rhinal cortices, which, in turn, projects onto the subicu-
lum [58]. These connections are reciprocal, as the subiculum projects back to the rhinal
cortices, which in turn project back to the cingulate cortex [58]. Similar to LD MA, HDMA
treatment decreased BGluM in limbic areas (rhinal cortex, subiculum). This effect was
extended in HDMA treated rats and a decrease in BGluM in the hippocampus, a region
strongly connected with both the subiculum and rhinal cortices, was also observed, in agree-
ment with previous in vitro 2- Deoxy-D-glucose (2DG) studies [70]. Overall, the results predict
that long-termMA treatment may affect brain function related to memory and navigation.
Two regions of the basal ganglia, the tail of the striatum and the globus pallidus, showed
decreased BGluM after chronic MA treatment, in agreement with previous observations in
human MA users [18] and with rat 2DG studies [70]. Decreased BGluM in these two basal gan-
glia areas may indicate MA effects on parts of the limbic system as well as the basal ganglia
motor loop. The tail of the striatum is part of the limbic basal ganglia with known anatomical
connections with the amygdala [71]. Since the striatum is a DA-rich region of the brain, effects
of MA treatment in this area can be attributed to the direct effects of the drug. On the other
hand, the globus pallidus is a region with little dopaminergic innervation and with strong stria-
tal inputs. Thus, decreased metabolic activity in this region may reflect an indirect consequence
of MA-induced changes on DA cells and the nigro-striato-pallidal projections, as previously
suggested [72].
The increased metabolic activity in the brain of MA users has been speculated to reflect neu-
roinflammation and gliosis [18]. In this study, the only brain region that showed increased
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BGluM, in conjunction with increased [3H]PK 11195 binding, was the insular cortex of LD
MA treated rats. However, regions that showed decreased BGluM also showed increases in
[3H]PK 11195 (rhinal cortex, cingulate cortex, striatum), suggesting that increased metabolic
activity is not necessarily a consequence of neuroinflammation.
Limitations of the study
The three experiments of the current study, MRI volumetrics, activated microglia assessment,
and BGluM assessment were performed in different groups of animals, which does not allow
correlation analyses that would shed more light into the associations between the three mea-
sures, without, however, providing proof of causality. The need for future studies, including a
study on how the time course of microglial activation corresponds to an increase in striatal vol-
ume and/or a stereological volume estimation in conjunction with microglial assessment in the
same tissue, and are deemed necessary.
MA was dissolved in saline, without further pH adjustments, according to previously pub-
lished protocols. Since the pH of aqueous MA solution is 6 [73] peripheral inflammatory effects
that would induce brain microglia activation [74] cannot be excluded, particularly since MA
was administered for a long period of time. On the other hand, human users also consume MA
hydrochloride, and the aqueous solutions of crystal meth are reported to be acidic, the majority
below 5.5 [75]. In addition, MA users take MA on a daily basis and for many years (e.g. see
[13]), a condition that we wished to reproduce in the current study. Taking all the above under
consideration and including the fact that the rats did not have visible distress signs, visible
signs of overall hyperalgesia or swelling and pain at or near the injection sites, we may conclude
that—in spite of its limitation regarding the pH—the animal model we chose reproduces sev-
eral aspects of human MA abuse and retains its clinical relevance. In future experiments, MA
should be dissolved in PBS or the pH of the NaCl solution should be adjusted to 7, with dilute
NaOH.
Summary
Overall, the current study shows an increase in striatal volume after prolonged treatment with
8 mg/kg/day MA, along with increased microglial activation in the striatum and decreased
BGluM in the caudal striatum. The increased microglial response extends beyond the striatum,
to distinct dopamine-poor brain regions, not showing volumetric changes. BGluM changes in
DA-related regions (globus pallidus, striatum) may be the result of a response to MA by the
dopaminergic system. In contrast, the changes in BGluM in other areas (cerebral cortex, hippo-
campus) suggest MA effects on other neurotransmitter pathways. BGluM changes in dopa-
mine-poor regions include increases in primary and higher-order sensory cortical areas,
insular and retrosplenial cortices, and the reticular formation, while decreases are observed in
the rhinal cortices, hippocampus, and subiculum.
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